Press Releases Johnson & Johnson Bulgaria S.E.

Equities

JNJ

US4781601046

End-of-day quote Bulgaria S.E. Other stock markets 06:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
140.6 ^EUR	+0.41%		+1.43%	-11.49%

May. 28	Sector Update: Health Care Stocks Fall Late Afternoon	MT
May. 28	Sector Update: Health Care Stocks Retreat Tuesday Afternoon	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis	May. 28	AQ
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis	May. 28	BU
Johnson & Johnson: Meet a nurse who leads clinical trials to find innovative cancer therapies	May. 24	AQ
Johnson & Johnson : advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA	May. 24	PU
Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation	May. 22	BU
Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences	May. 22	AQ
TREMFYA (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission	May. 21	AQ
Novel biologic could offer ulcerative colitis symptomatic remission	May. 21	AQ
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation	May. 21	AQ
Johnson & Johnson : to Participate in the 2024 RBC Capital Markets Global Healthcare Conference Transcript	May. 17	PU
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment	May. 16	BU
Johnson & Johnson : to Participate in the BofA Securities Health Care Conference Transcript	May. 15	PU
Johnson & Johnson : to Participate in the 2024 RBC Capital Markets Global Healthcare Conference Press Release	May. 15	PU
Johnson & Johnson : to Participate in the BofA Securities Health Care Conference Press Release	May. 15	PU
Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	May. 08	BU
Intravesical drug delivery system exhibits bladder cancer benefit	May. 07	AQ
Johnson & Johnson - Phase 2 data for ERLEADA plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate	May. 06	AQ
Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024	May. 06	AQ
Johnson & Johnson - TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer	May. 06	AQ
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA (guselkumab) for treatment of patients with ulcerative colitis and Crohn's disease	May. 03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST